|Clostridium botulinum stained with gentian violet.|
van Ermengem, 1896
Clostridium botulinum is a Gram-positive, rod-shaped, anaerobic, spore-forming, motile bacterium with the ability to produce the neurotoxin botulinum. The botulinum toxin can cause a severe flaccid paralytic disease in humans and animals and is the most potent toxin known to humankind, natural or synthetic, with a lethal dose of less than 1 μg in humans.
C. botulinum is a diverse group of bacteria initially grouped together by their ability to produce botulinum toxin and now known as four distinct groups, C. botulinum groups I-IV. C. botulinum groups I-IV as well as some strains of Clostridium butyricum and Clostridium baratii are the bacteria responsible for producing botulinum toxin.
C. botulinum is responsible for foodborne botulism (ingestion of preformed toxin), infant botulism (intestinal infection with toxin forming C. botulinum), and wound botulism (infection of a wound with C. botulinum). C. botulinum produces heat resistant endospores that are commonly found in soil and allow for survival in adverse conditions.
C. botulinum is a Gram-positive, rod-shaped, spore-forming bacterium. It is an obligate anaerobe, meaning that oxygen is poisonous to the cells. However, C. botulinum tolerates traces of oxygen due to the enzyme superoxide dismutase (SOD) which is an important antioxidant defense in nearly all cells exposed to oxygen. C. botulinum is only able to produce the neurotoxin during sporulation, which can only happen in an anaerobic environment. Other bacterial species produce spores in an unfavorable growth environment to preserve the organism's viability and permit survival in a dormant state until the spores are exposed to favorable conditions.
C. botulinum is divided in to four distinct phenotypic groups (groups I-IV) and is also classified into seven serotypes (types A-G) based on the antigenicity of the botulinum toxin that is produced. Recently an eighth serotype (type H) has been described.
The classification into four physiologic groups is based on the ability of the organism to digest complex proteins. Studies at the DNA and rRNA level support the subdivision of the species into groups I-IV. Most outbreaks of human botulism are caused by group I (proteolytic) or II (non-proteolytic) C. botulinum. Group III organisms mainly cause diseases in animals. There has been no record of Group IV C. botulinum causing human or animal disease.
Neurotoxin production is the unifying feature of the species C. botulinum. Eight types of toxins have been identified (including the recently described type H) that are allocated a letter (type A-H). All toxins are rapidly destroyed at 100 °C; however, they are resistant to degradation by enzymes found in the gastrointestinal tract. This allows for ingested toxin to be absorbed from the intestines into the bloodstream.
Most strains produce one type of neurotoxin but strains producing multiple toxins have been described. Clostridium botulinum producing B and F toxin types have been isolated from human botulism cases in New Mexico and California. The toxin type has been designated Bf as the type B toxin was found in excess to the type F. Similarly, strains producing Ab and Af toxins have been reported. There is evidence that the neurotoxin genes have been the subject of horizontal gene transfer, possibly from a viral source. This theory is supported by the presence of integration sites flanking the toxin in some strains of C. botulinum. However, these integrations sites are degraded indicating that the C. botulinum acquired the toxin genes quite far into the evolutionary past.
Botulinum toxin types
Only botulinum toxin types A, B, E, F, and H cause disease in humans. Types A, B, and E are associated with foodborne illness with type E specifically associated with fish products. Type C produces limberneck in birds and type D causes botulism in other mammals. There is no disease associated with type G. The "gold standard" for determining toxin type is a mouse bioassay, but the genes for types A, B, E, and F can now be readily differentiated using quantitative PCR (PCR).
A few strains from organisms genetically identified as other Clostridium species have caused human botulism: Clostridium butyricum has produced type E toxin and Clostridium baratii had produced type F toxin. The ability of C. botulinum to naturally transfer neurotoxin genes to other clostridia is concerning, especially in the food industry where preservation systems are designed to destroy or inhibit only C. botulinum but not other Clostridium species.
An eighth toxin, type H, was discovered by researchers at the California Department of Public Health in 2013. With a lethal dose of 2 ng by injection or 13 ng by inhalation, it was deemed the most toxic substance on Earth.
|A, B, F||B, E, F||C, D||G|
|C. sporogenes, C. putrificum||C. butyricum, C. beijerinickii||C. haemolyticum, C. novyi type A||C. subterminale, C. haemolyticum|
In the laboratory Clostridium botulinum is usually isolated in tryptose sulfite cycloserine (TSC) growth media in an anaerobic environment with less than 2% of oxygen. This can be achieved by several commercial kits that use a chemical reaction to replace O2 with CO2. C. botulinum is a lipase positive microorganism that grows between pH of 4.8 and 7 and can not use lactose as a primary carbon source, characteristics important during a biochemical identification.
Clostridium botulinum was first recognized and isolated in 1895 by Emile van Ermengem from home cured ham implicated in a botulism outbreak. The isolate was originally named Bacillus botulinus, after the Latin word for sausage, botulus. ("Sausage poisoning" was a common problem in 18th- and 19th-century Germany, and was most likely caused by botulism) However, isolates from subsequent outbreaks were always found to be anaerobic spore formers, so Ida A. Bengtson proposed that the organism be placed into the genus Clostridium as the Bacillus genus was restricted to aerobic spore-forming rods.
Since 1959 all species producing the botulinum neurotoxins (types A-G) have been designated C. botulinum. Substantial phenotypic and genotypic evidence exists to demonstrate heterogeneity within the species. This has led to the reclassification of C. botulinum type G strains as a new species Clostridium argentinense.
The complete genome of C. botulinum has been sequenced at Sanger.
Botulism poisoning can occur due to improperly preserved or home-canned, low-acid food that was not processed using correct preservation times and/or pressure.
Symptoms of botulism
Foodborne botulism "Signs and symptoms of foodborne botulism typically begin between 18 and 36 hours after the toxin gets into your body, but can range from a few hours to several days, depending on the amount of toxin ingested."
- Double vision
- Blurred vision
- Drooping eyelid
- Nausea, vomiting, and abdominal cramps
- Slurred speech
- Trouble breathing
- Difficulty in swallowing
- Dry mouth
- Muscle weakness
- Reduced or absent deep tendon reactions, such as in the knee.
Wound Botulism Most people who develop wound botulism inject drugs several times a day, so it's difficult to determine how long it takes for signs and symptoms to develop after the toxin enters the body. Most common in people who inject black tar heroin, wound botulism signs and symptoms include:
- Difficulty swallowing or speaking
- Facial weakness on both sides of the face
- Blurred or double vision
- Drooping eyelids
- Trouble breathing
Infant Botulism If infant botulism is related to food, such as honey, problems generally will begin within 18 to 36 hours after the toxin enters the baby's body. Signs and symptoms include:
- Constipation (often the first sign)
- Floppy movements due to muscle weakness and trouble controlling the head
- Weak cry
- Drooping eyelids
- Difficulty sucking or feeding
Beneficial effects of botulinum toxin: Purified botulinum toxin is diluted by a physician for treatment:
- 1 - Congenital pelvic tilt
- 2 - Spasmodic dysphasia (the inability of the muscles of the larynx)
- 3 - Achalasia (esophageal stricture)
- 4 - Strabismus (crossed eyes)
- 5 - Paralysis of the facial muscles
- 6 - Failure of the cervix
- 7 - Blinking frequently
- 8 - According to the BBC, an American group is trying Clostridium Type E to deliver anti-cancer drugs directly to the tumor.
Clostridium botulinum in different geographical locations
Type A C. botulinum predominates the soil samples from the western regions while type B is the major type found in eastern areas. The type B organisms were of the proteolytic type I. Sediments from the Great Lake regions were surveyed after outbreaks of botulism among commercially reared fish and only type E spores were detected. It has been noted in a survey that type A strains were isolated from soils that were neutral to alkaline (average pH 7.5) while type B strains were isolated from slightly acidic soils (average pH 6.25).
Clostridium botulinum type E is prevalent in aquatic sediments in Norway and Sweden, Denmark, the Netherlands, the Baltic coast of Poland and Russia. It was then suggested that the type E C. botulinum is a true aquatic organism, which was indicated by the correlation between the level of type E contamination and flooding of the land with seawater. As the land dried, the level of type E decreased and type B became dominant.
In soil and sediment from the United Kingdom, C. botulinum type B predominates. In general, the incidence is usually lower in soil than in sediment. In Italy, a survey was conducted in the vicinity of Rome, and a low level of contamination was found; all strains were proteolytic C. botulinum type A or B.
Clostridium botulinum type A was found to be present in soil samples from mountain areas of Victoria. Type B organisms were detected in marine mud from Tasmania. Type A C. botulinum have been found in Sydney suburbs and types A and B were isolated from urban areas. In a well defined area of the Darling-Downs region of Queensland, a study showed the prevalence and persistence of C. botulinum type B after many cases of botulism in horses.
A "mouse protection" or "mouse bioassay" test determines the type of C. botulinum toxin present using monoclonal antibodies. An enzyme-linked immunosorbent assay (ELISA)with digoxigenin-labeled antibodies can also be used to detect the toxin, and quantitative PCR can detect the toxin genes in the organism.
Clostridium botulinum is also used to prepare the medicaments Botox, Dysport, Xeomin, and Neurobloc used to selectively paralyze muscles to temporarily relieve muscle function. It has other "off-label" medical purposes, such as treating severe facial pain, such as that caused by trigeminal neuralgia.
Botulin toxin produced by C. botulinum is often believed to be a potential bioweapon as it is so potent that it takes about 75 nanograms to kill a person (LD50 of 1 ng/kg, assuming an average person weighs ~75 kg); 1 kilogram of it would be enough to kill the entire human population. For comparative purposes, a quarter of a typical grain of sand's weight (350 ng) of botulinum toxin would constitute a lethal dose for humans.
Clostridium botulinum is a soil bacterium. The spores can survive in most environments and are very hard to kill. They can survive the temperature of boiling water at sea level, thus many foods are canned with a pressurized boil that achieves an even higher temperature, sufficient to kill the spores.
Growth of the bacterium can be prevented by high acidity, high ratio of dissolved sugar, high levels of oxygen, very low levels of moisture or storage at temperatures below 3 °C (38 °F) for type A. For example in a low acid, canned vegetable such as green beans that are not heated hot enough to kill the spores (i.e., a pressurized environment) may provide an oxygen free medium for the spores to grow and produce the toxin. On the other hand, pickles are sufficiently acidic to prevent growth; even if the spores are present, they pose no danger to the consumer. Honey, corn syrup, and other sweeteners may contain spores but the spores cannot grow in a highly concentrated sugar solution; however, when a sweetener is diluted in the low oxygen, low acid digestive system of an infant, the spores can grow and produce toxin. As soon as infants begin eating solid food, the digestive juices become too acidic for the bacterium to grow.
- Peck, MW (2009). "Biology and genomic analysis of Clostridium botulinum.". Advances in microbial physiology 55: 183–265, 320. doi:10.1016/s0065-2911(09)05503-9. PMID 19573697.
- Lindström, M; Korkeala, H (Apr 2006). "Laboratory diagnostics of botulism.". Clinical Microbiology Reviews 19 (2): 298–314. doi:10.1128/cmr.19.2.298-314.2006. PMID 16614251.
- (2010). Chapter 29. Clostridium, Peptostreptococcus, Bacteroides, and Other Anaerobes. In Ryan K.J., Ray C (Eds), Sherris Medical Microbiology, 5th ed. ISBN 978-0071604024
- Doyle, Michael P. (2007). Food Microbiology: Fundamentals and Frontiers. ASM Press. ISBN 1-55581-208-2.
- Peck MW, Stringer SC, Carter AT. Clostridium botulinum in the post-genomic era. Food Microbiol. 2011;28(2):183-91. doi:10.1016/j.fm.2010.03.005 PMID 21315972
- Shukla HD, Sharma SK. Clostridium botulinum: a bug with beauty and weapon. Crit Rev Microbiol. 2005;31(1):11-8. PMID 15839401
- MacKenzie, Debora (14 October 2013). "New botox super-toxin has its details censored". NewScientist. Retrieved 15 October 2013.
- L. V. Holdeman, J. B. Brooks. 1970. Variation among strains of Clostridium botulinum and related clostridia. Protocols of the first U.S-Japan conference on Toxic Microorganisms. pp. 278–286
- L. D. S. Smith, G. Hobbs. 1974. Genus III Clostridium Prazmowski 1880, 23. In R. E. Buchanan, N. E. gibbons (eds.), Bergey’s Manual of Determinative Bacteriology, 8th ed. William & Wilkins, Baltimore. pp. 551–572. ISBN 978-0683006032
- Hatheway, C. L., McCroskey, L. M. (1987). "Examination of faeces for diagnosis of infant botulism in 336 patients". J. Clin. Microbiol 25 (12): 2334–2338. PMC 269483. PMID 3323228.
- (2013). Chapter 11. Spore-Forming Gram-Positive Bacilli: Bacillus and Clostridium Species. In Brooks G.F., Carroll K.C., Butel J.S., Morse S.A., Mietzner T.A. (Eds), Jawetz, Melnick, & Adelberg's Medical Microbiology, 26th ed. ISBN 978-0071790314
- Satterfield, B. A.; Stewart, A. F.; Lew, C. S.; Pickett, D. O.; Cohen, M. N.; Moore, E. A.; Luedtke, P. F.; O'Neill, K. L.; Robison, R. A. et al. (2010). "A quadruplex real-time PCR assay for rapid detection and differentiation of the Clostridium botulinum toxin genes A, B, E and F". J Med Microbiol 59 (Pt 1): 55–64. doi:10.1099/jmm.0.012567-0. PMID 19779029.
- Aureli, P.; Fenicia, L.; Pasolini, B.; Gianfrancesche, M.; Mccroskey, J. M.; Hatheway, C. L. (1986). "Two cases of type E infant botulism caused by neurotoxigenic Clostridium botulinum in Italy". J. Infect. Dis. 154 (2): 207–211. doi:10.1093/infdis/154.2.207. PMID 3722863.
- Hall, J. D.; McCroskey, L. M.; Pincomb, B. J.; Hatheway, C. L. (1985). "Isolation of an organism resembling Clostridium baratii which produces a type F botulinal toxin from an infant with botulism". J. Clin. Microbiol 21 (4): 654–655. PMC 271744. PMID 3988908.
- Notermans, S., Havellar, A. H. (1980). "Removal and inactivation of botulinum toxin during production of drinking water from surface water". Antonie van Leeuwenhoek 46 (5): 511–514. doi:10.1007/BF00395840.
- . (2005). Brock Biology of Microorganisms (11th ed.). Prentice Hall. ISBN 0-13-144329-1.
- E. van Ergmengem. 1897. Über einen neuen anaeroben Bacillus und seine Beziehungen Zum Botulismus. Zentralbl. Hyg. Infektionskr. 26:1–8.
- Frank J. Erbguth. Historical notes on botulism, Clostridium botulinum, botulinum toxin, and the idea of the therapeutic use of the toxin. Movement Disorders. Volume 19, Issue S8, pages S2-S6, March 2004.
- I. A. Bengston. 1924. Studies on organisms concerned as causative factors in botulism. Hyg. Lab. Bull. 136:101
- J. C. Suen, C. L. Hatheway, A. G. Steigerwalt, D. J. Brenner. 1988, Clostridium argentinense sp.nov.: a genetically homogeneous group composed of all strains of Clostridium botulinum type G and some nontoxigenic strains previously identified as Clostridium subterminale or Clostridium hastiforme. Int. J. Sys. Bacteriol. 38:375–381.
- Judicial Commission of the International Committee on Systematic Bacteriology (1999) Rejection of Clostridium putrificum and conservation of Clostridium botulinum and Clostridium sporogenes Opinion 69. International Journal of Systematic Bacteriology. 49:339.
- Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Hauer J, Layton M, Lillibridge S, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Swerdlow DL, Tonat K (February 2001). "Botulinum toxin as a biological weapon: medical and public health management". JAMA: The Journal of the American Medical Association 285 (8): 1059–70. PMID 11209178.Retrieved on 2012-02-16.
- A. H. W. Hauschild. 1989. Clostridium botulinum. In M. P. Doyle (ed.), Food-borne Bacterial Pathogens. Marcel Dekker, New York. Pp. 111–189
- Bott, T. L.; Johnson, J.; Foster, E. M.; Sugiyama, H. (1968). "Possible origin of the fish incidences of Clostridium botulinum type E in an inland bay (Green Bay of Lake Michigan)". J. Bacteriol 95: 1542.
- M. W. Eklund, M. E. Peterson, F. T. Poysky, L. W. Peck, J. F. Conrad. 1982. Botulism in juvenile Coho salmon (Onocorhynchus kisutch) in the United States. Aquaculture 27:1–11
- M. W. Eklund, F. T. Poysky M. E. Peterson, L. W. Peck, Brunson. 1984. Type E botulism in salmonids and conditions contributing to outbreaks. Aquaculture 41:293–309.
- A. Johannsen. 1963. Clostridium botulinum in Sweden and the adjacent waters. J. Appl. Bacteriol. 26:43–47.
- Huss, H. H. (1980). "Distribution of Clostridium botulinum". Appl. Environ. Microbiol 39 (4): 764–769. PMC 291416. PMID 6990867.
- Creti, R.; Fenicia, J.; Aureli, P. (1990). "Occurrence of Clostridium botulinum in the soil of the vicinity of Rome". Curr. Microbiol 20: 317. doi:10.1007/bf02091912.
- C. E. Eales, J. M. Gillespie. 1947. the isolation of Clostridium botulinum type A from Victorian soils. Aust. J. Sci. 10:20–21.
- D. f. Ohye, W. J. Scott. 1957. Studies in the physiology of Clostridium botulinum type E. Aust. L. Biol. Sci. 10:85–94.
- Shashi K. Sharma, Joseph. L. Ferreira, Brian S. Eblen and Richard C. Whitingand. Detection of Type A, B, E, and F Clostridium botulinum Neurotoxins in Foods by Using an Amplified Enzyme-Linked Immunosorbent Assay with Digoxigenin-Labeled Antibodies. Appl. Environ. Microbiol. February 2006 vol. 72 no. 2 1231-1238. doi:10.1128/AEM.72.2.1231-1238.2006
- Fleming, Diane O. "Biological Safety: principles and practices". ASM Press 2000: 267.
- Pathema-Clostridium Resource
- Jeremy Sobel (2005). "Botulism". Clinical Infectious Diseases 41 (8): 1167–1173. doi:10.1086/444507. PMID 16163636.
- Current research on Clostridium botulinum at the Norwich Research Park